On Friday, Shares of T-Mobile US Inc (NASDAQ:TMUS), lost - 0.94% to $36.00.
Nasdaq (NDAQ), declared the results of the annual re-ranking of the NASDAQ-100 Index (Nasdaq:NDX), which will become effective before market open on Monday, December 21, 2015.
The following seven companies will be added to the Index: Ctrip.com International, Ltd. (CTRP), Endo International plc (ENDP), Expedia, Inc. (EXPE), Maxim Integrated Products, Inc. (MXIM), Norwegian Cruise Line Holdings Ltd. (NCLH), T-Mobile US, Inc. (TMUS) and Ulta Salon, Cosmetics & Fragrance, Inc. (ULTA).
The NASDAQ-100 Index is composed of the 100 largest non-financial companies listed on The Nasdaq Stock Market® and dates to January 1985 when it was launched together with the NASDAQ Financial-100 Index®, which is comprised of the 100 largest financial stocks on Nasdaq®. These indexes act as benchmarks for financial products such as options, futures, and funds. The NASDAQ-100 is re-ranked each year in December, timed to coincide with the quadruple witch expiration Friday of the quarter.
T-Mobile US, Inc., together with its auxiliaries, provides mobile communications services in the United States, Puerto Rico, and the U.S. Virgin Islands. The company offers voice, messaging, and data services in the postpaid, prepaid, and wholesale markets.
Shares of Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), declined -4.57% to $6.05, during its last trading session.
ARIAD Pharmaceuticals, declared that it will continue negotiations with the Economic Committee on Health Care Products in France regarding pricing and reimbursement for Iclusig® (ponatinib) into 2016. The Company had formerly anticipated reaching agreement by year-end 2015. As a result, ARIAD now anticipates its global product revenue for Iclusig in 2015 to be $110 million to $115 million, not taking into account France, contrast to our previous guidance of $130 million to $140 million. The Company estimates shipments of Iclusig to patients in France for 2015 to be about $9 million, and the cumulative value of shipments through year-end 2015 to be about $26 million.
“We are happy with the continued growth of our business in France as evidenced by increasing product shipments and look forward to successful resolution of price,” stated Marty J. Duvall, executive vice president and chief commercial officer of ARIAD. ”We continue to promote and sell Iclusig in France with the objective of assisting patients and driving long-term brand value for key stakeholders.”
ARIAD’s formerly stated revenue guidance for 2015 assumed the completion of pricing and reimbursement negotiations in France by year-end. ARIAD will record revenue related to cumulative shipments in France upon completion of pricing and reimbursement negotiations, net of any amounts that will be refunded to the French health authorities as a result of these negotiations, which we now anticipate will be accomplished in 2016.
ARIAD Pharmaceuticals, Inc., an oncology company, engages in the discovery, development, and commercialization of medicines for cancer patients. The company offers Iclusig (ponatinib), a tyrosine kinase inhibitor (TKI) for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia in the United States, Europe, and other territories.
Finally, Cytori Therapeutics Inc (NASDAQ:CYTX), ended its last trade with - 15.75% loss, and closed at $0.2647.
Cytori Therapeutics, declared that it has received formal confirmation from The Nasdaq Stock Market LLC (“Nasdaq”) that Cytori’s request for an oral hearing with the Nasdaq Hearing Panel (“Panel”) has been granted. The hearing will occur on January 21, 2016 at Nasdaq’s Washington, D.C. offices. During the period before the hearing, Cytori’s common stock will continue to trade on The Nasdaq Global Market (“NGM”). Cytori intends to present a plan to the Hearing Panel that will allow it to remain on the NGM. As an alternative, Cytori believes that it is fully eligible to transfer to The Nasdaq Capital Market (“NCM”), in which case it would be entitled to rely on a second 180-day period (retroactively measured from December 1, 2015). During this second 180-day period, if required Cytori will be in a position to effect a reverse stock split to bring the bid price of its common stock above the minimum $1 threshold.
As Cytori stated on December 7, 2015, it received a determination letter from the Nasdaq staff stating that it has yet to regain compliance with the minimum bid price requirement for continued listing set forth in Nasdaq Marketplace Rule 5450(a)(1). Upon receipt of the determination letter, Cytori chose to pursue a hearing in front of the Hearing Panel rather than seek an immediate transfer to the NCM because administration believes that pursuing a hearing allows it the opportunity to present a comprehensive plan to regain compliance with NGM continued listing requirements.
Cytori Therapeutics, Inc., a biotechnology company, develops cell therapeutics for specific diseases and medical conditions. The company primarily provides Cytori Cell Therapy comprising of a heterogeneous population of specialized cells, counting stem cells for the treatment of patients with scleroderma hand dysfunction, orthopedic disorders, cardiovascular disease, urinary incontinence, and thermal burns combined with radiation injury. It also offers Celution System devices and consumable sets, and other ancillary products for the customers developing new therapeutic applications for Cytori Cell Therapy in Europe, Japan, and other regions.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.